Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
46.13
-0.04 (-0.09%)
At close: Oct 16, 2026, 4:00 PM EDT
46.39
+0.26 (0.56%)
Pre-market: Oct 19, 2026, 4:25 AM EDT
Qiagen Employees
Qiagen had 5,700 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Qiagen the 5,144th largest employer in the world and 1,071st in the United States.
Employees
5,700
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$368,485
Profits / Employee
$71,810
Market Cap
9.54B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5,700 | 0 | - |
| Dec 31, 2024 | 5,700 | -267 | -4.47% |
| Dec 31, 2023 | 5,967 | -211 | -3.42% |
| Dec 31, 2022 | 6,178 | 150 | 2.49% |
| Dec 31, 2021 | 6,028 | 418 | 7.45% |
| Dec 31, 2020 | 5,610 | 514 | 10.09% |
| Dec 31, 2019 | 5,096 | 144 | 2.91% |
| Dec 31, 2018 | 4,952 | 264 | 5.63% |
| Dec 31, 2017 | 4,688 | 4 | 0.09% |
| Dec 31, 2016 | 4,684 | 125 | 2.74% |
| Dec 31, 2015 | 4,559 | 220 | 5.07% |
| Dec 31, 2014 | 4,339 | 324 | 8.07% |
| Dec 31, 2013 | 4,015 | 16 | 0.40% |
| Dec 31, 2012 | 3,999 | 61 | 1.55% |
| Dec 31, 2011 | 3,938 | 351 | 9.79% |
| Dec 31, 2010 | 3,587 | 92 | 2.63% |
| Dec 31, 2009 | 3,495 | 454 | 14.93% |
| Dec 31, 2008 | 3,041 | 379 | 14.24% |
| Dec 31, 2007 | 2,662 | 708 | 36.23% |
| Dec 31, 2006 | 1,954 | 365 | 22.97% |
| Dec 31, 2005 | 1,589 | 267 | 20.20% |
| Dec 31, 2004 | 1,322 | -231 | -14.87% |
| Dec 31, 2003 | 1,553 | -98 | -5.94% |
| Dec 31, 2002 | 1,651 | 94 | 6.04% |
| Dec 31, 2001 | 1,557 | 242 | 18.40% |
| Dec 31, 2000 | 1,315 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Labcorp Holdings | 71,000 |
| ICON Public Limited Company | 40,100 |
| Charles River Laboratories International | 19,700 |
| Revvity | 11,000 |
| RadNet | 9,276 |
| Medpace Holdings | 6,200 |
| Sotera Health Company | 3,000 |
| Guardant Health | 2,506 |
QGEN News
- 4 days ago - Qiagen price target raised to $55 from $50 at JPMorgan - TheFly
- 5 days ago - QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis - Business Wire
- 9 days ago - Qiagen price target raised to $50 from $49 at BofA - TheFly
- 12 days ago - Qiagen announces new AI capabilities for researchers - TheFly
- 12 days ago - QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery - Business Wire
- 12 days ago - Barclays upgrades Qiagen to Overweight ahead of Q3 report - TheFly
- 12 days ago - Qiagen upgraded to Overweight from Equal Weight at Barclays - TheFly
- 20 days ago - Qiagen: QIAstat-Dx bloodstream infection portfolio now available to U.S. labs - TheFly